Early reduction of cyclosporine A / mycophenolate mofetil based on lineage-specific chimerism after allogeneic transplantation

Phase 4, open-label, single-arm trial of mycophenolate mofetil and cyclosporine in hematopoietic malignancies and Hematopathy, sponsored by Leipzig University. Primary endpoint: Relapse rate after decline of lineage-specific chimerism and risk-adapted immunosuppression reduction. Started Aug 2007; status: completed.